




Chinese Pharmaceutical Association  
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

[www.elsevier.com/locate/apsb](http://www.elsevier.com/locate/apsb)  
[www.sciencedirect.com](http://www.sciencedirect.com)



REVIEW

## Apolipoprotein E and Alzheimer's disease



Benjamin R. Troutwine<sup>a,b</sup>, Laylan Hamid<sup>b</sup>, Colton R. Lysaker<sup>b,c</sup>,  
Taylor A. Strope<sup>b,c</sup>, Heather M. Wilkins<sup>a,b,c,\*</sup>

<sup>a</sup>Department of Neurology University of Kansas Medical Center, Kansas City, KS 66160, USA

<sup>b</sup>University of Kansas Alzheimer's Disease Center, Kansas City, KS 66160, USA

<sup>c</sup>Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA

Received 26 August 2021; received in revised form 30 September 2021; accepted 7 October 2021

### KEY WORDS

Apolipoprotein E;  
Alzheimer's disease;  
Mitochondria;  
Neuroinflammation;  
Amyloid beta;  
Tau

**Abstract** Genetic variation in apolipoprotein E (*APOE*) influences Alzheimer's disease (AD) risk. *APOE*  $\epsilon 4$  alleles are the strongest genetic risk factor for late onset sporadic AD. The AD risk is dose dependent, as those carrying one *APOE*  $\epsilon 4$  allele have a 2–3-fold increased risk, while those carrying two  $\epsilon 4$  alleles have a 10–15-fold increased risk. Individuals carrying *APOE*  $\epsilon 2$  alleles have lower AD risk and those carrying *APOE*  $\epsilon 3$  alleles have neutral risk. *APOE* is a lipoprotein which functions in lipid transport, metabolism, and inflammatory modulation. Isoform specific effects of *APOE* within the brain include alterations to  $A\beta$ , tau, neuroinflammation, and metabolism. Here we review the association of *APOE* with AD, the *APOE* isoform specific effects within brain and periphery, and potential therapeutics.

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\*Corresponding author.

E-mail address: [hwilkins@kumc.edu](mailto:hwilkins@kumc.edu) (Heather M. Wilkins).

Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2021.10.002>

2211-3835 © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Overview

Apolipoprotein E (APOE) is a lipid binding protein and is the predominant cholesterol transport protein in the brain. While the main function of APOE is lipid transport, it also binds and interacts with inflammatory components such as lipopolysaccharides (LPS), amyloid beta ( $A\beta$ ), beta-glucans, and lipoteichoic acids<sup>1,2</sup>. This function is believed to facilitate clearance of inflammatory and pathogenic molecules suggesting a role for APOE in innate immunity. APOE was discovered in 1975 but its full structure was not resolved until 2011<sup>2–4</sup>. APOE is synthesized and secreted largely in the liver, brain, macrophages, and skin<sup>1,2,5</sup>.

In humans, three major isoforms of *APOE* exist. These are known as  $\epsilon 2$ ,  $\epsilon 3$ , and  $\epsilon 4$ . These three alleles arose around 7.5 million years ago following the primate–human split<sup>6,7</sup>. Mutations between human and primate *APOE* are non-synonymous and alter protein function.  $\epsilon 4$  was the first allele, with four amino acid changes between human and primates (A18T, T61R, A135V, and V174L)<sup>1,6,7</sup>. Approximately 150,000–220,000 years ago, further amino acid changes to *APOE* resulted in the  $\epsilon 3$  allele (R112C)<sup>1,6,7</sup>. The  $\epsilon 2$  allele originated approximately 80,000 years ago with another amino acid change (R158C)<sup>1,6,7</sup>. *APOE* is on chromosome 19, and the gene is composed of four exons and three introns<sup>1</sup>. The amino acid changes between *APOE* alleles alter the structure and function of the protein<sup>1,6</sup>.

The estimated timeline of allele changes in the human population are based on assumption of neutral selectivity<sup>6,8</sup>. Neutral selectivity theory postulates most genetic variation is due to a stochastic process conveying no selection advantage at the molecular level. The *APOE*  $\epsilon 3$  allele has the highest penetrance in Asia (followed by Europe and Africa). This suggests an Asia origin for the  $\epsilon 3$  allele following human migration<sup>1,6</sup>. Selective pressures on *APOE* alleles are contributed to age-related brain function, resistance to pathogens (such as malaria), climate, fertility, and diet/nutrient sources<sup>6</sup>. Therefore, the assumption of neutral selectivity may render the allele emergence timeline presented above inaccurate<sup>6</sup>.

$\epsilon 3$  is the most common isoform of *APOE*, accounting for approximately 80% of alleles in humans. The prevalence of *APOE* alleles varies by continent and latitude. For example, *APOE*  $\epsilon 3$  alleles constitute 85% of alleles in Asia, 69% in Africa, 82% in North America, 77% in South America, and 79% in Europe<sup>9</sup>.  $\epsilon 2$  and  $\epsilon 4$  are less common, accounting for approximately 5%–10% and 10%–15% of *APOE* alleles found in humans. *APOE*  $\epsilon 4$  prevalence varies across different populations with 40% penetrance in Central Africa, 37% in Oceania, and 26% in Australia<sup>6</sup>. In Europe, there is a “gradient” of *APOE*  $\epsilon 4$  allele distribution among populations. With high  $\epsilon 4$  allele prevalence in both northern Europe and Asia at approximately 25% and low allele prevalence in South China and the Mediterranean area at less than 10%<sup>6,10,11</sup>.  $\epsilon 2$  allele distribution and prevalence vary by population as well, with a lack of alleles in African indigenous populations and Australian aborigines. The *APOE*  $\epsilon 2$  allele is higher than average in Africa with 9.9% penetrance and Oceania populations at 11.1%<sup>6,9</sup>. Variance of *APOE* alleles across climates and populations may reflect selective advantages for specific alleles in specific climates.

In Alzheimer’s disease (AD) populations,  $\epsilon 4$  alleles are over-represented<sup>12–14</sup>. Approximately 60%–80% of subjects afflicted with AD carry a  $\epsilon 4$  allele<sup>1,12,15,16</sup>. The AD risk conferred by *APOE*  $\epsilon 4$  is dose dependent<sup>15</sup>. Those carrying one  $\epsilon 4$  allele have a 2–3-fold increased AD risk, while those carrying two  $\epsilon 4$  alleles

have a 10–15-fold increased AD risk<sup>1,15,16</sup>. Conversely,  $\epsilon 2$  allele carriers may have a reduced AD risk<sup>1,15,16</sup>.

The protein product of *APOE* is a 317 amino acid peptide. The first 18 amino acids are cleaved co-translationally to form a mature 299 amino acid protein<sup>1</sup>. Mouse APOE is considered APOE3-like due to it carrying a threonine at amino acid position 61, but it only shares approximately 70% homology with human APOE<sup>6</sup>. Mouse APOE is six amino acids shorter. The lack of homology with human APOE brings to light possible issues with prior mouse studies focusing on single amino acid mutations in mouse APOE and their relevance to human APOE function<sup>6</sup>.

APOE isoforms exhibit differential post-translational modifications. APOE is sialylated which changes isoelectric points of the isoforms. APOE  $\epsilon 4$  has a +2 charge,  $\epsilon 3$  a +1 charge, and  $\epsilon 2$  a neutral charge<sup>1</sup>. Various levels of sialylation alter these charges for each isoform. Variable isoelectric points are due to the arginine–cysteine changes among the isoforms and sialylation differences are due to *O*-linked glycosylation at threonine 194<sup>16,17</sup>. Non-sialylated forms lack neutral sugars<sup>16–18</sup>. Sialylation increases the APOE variation observed in circulation<sup>16,17</sup>.

Within APOE amino acids 136–150 are critical for receptor and heparin binding<sup>1,19–22</sup>. The C-terminus is rich in  $\alpha$ -helices and functions in lipid binding. Binding of lipids to these residues allows receptor access to residues 136–150. Residues 244–272 interact directly with lipid particles. APOE  $\epsilon 3$  and  $\epsilon 4$  bind to low density lipoprotein (LDL) receptors with similar affinities, while  $\epsilon 2$  has a slightly lower affinity (2% or 50 times weaker)<sup>23</sup>. APOE  $\epsilon 2$  and  $\epsilon 3$  both bind to smaller phospholipid-enriched high-density lipoproteins (HDL) but  $\epsilon 4$  preferentially binds to triglyceride rich/larger very low-density lipoproteins (VLDL). These binding preferences are accounted for with differences in protein domain interactions between the N and C termini of the isoforms. The structure/function relationship of APOE isoforms have been reviewed elsewhere<sup>1,2,4,6,20–22</sup>. Here we will review the role of APOE in lipid metabolism in the periphery and its contributions to AD risk within the brain.

## 2. APOE and lipid metabolism


APOE is secreted from the liver with VLDL particles. In the small intestine chylomicrons (or ultra-low-density lipoproteins) are synthesized and combine with APOE secreted by the liver<sup>24–26</sup>. Within the central nervous system, ATP binding cassette subfamily A member 1 (ABCA1) and ATP binding cassette subfamily G member 1 (ABCG1) are critical for the transfer of cholesterol and phospholipids to APOE to form lipoproteins<sup>27</sup>. During circulation, VLDL and chylomicrons become enriched with APOE<sup>1,24–26</sup>. Upon interaction with endothelial cells, lipoprotein lipase hydrolyzes the triglycerides from the APOE containing lipoproteins, releasing fatty acids for energy metabolism. APOE functions to transport lipids in endocrine (from liver to distant tissues) and paracrine (within the same tissue type) mechanisms. APOE can redistribute lipids across tissue and cell types<sup>1</sup>.

APOE influences lipid metabolism by acting as a ligand for receptors. APOE lipoproteins interact with LDL receptors to regulate levels of VLDL and LDL<sup>1,24,25,28,29</sup>. A second receptor pathway for APOE lipoproteins is the heparan sulfate proteoglycan (HSPG)/low density lipoprotein receptor-related protein (LRP) pathway<sup>1,25,30</sup>. The LRP pathway functions mainly in the liver and is reviewed elsewhere<sup>1,25,28–30</sup>. APOE regulates both catabolic and anabolic lipid metabolism. Increased APOE synthesis, plasma levels, or liver secretion is associated with

increased VLDL synthesis and secretion<sup>1</sup>. APOE accumulation on lipoproteins can reduce the lipolysis of lipoprotein triglycerides<sup>1</sup>. This indicates a self-feedback inhibition mechanism for APOE function. APOE induces influx and efflux of cholesterol from cells<sup>2,31</sup>. As a lipid transport protein, APOE is integrated into lipid metabolism across diverse tissue and cell types as shown in Fig. 1.

*APOE* isoforms differentially affect blood lipid profiles in humans<sup>1,32</sup>. *APOE*  $\epsilon 2$  is associated with increased levels of APOE/triglycerides and decreased levels of APOB/cholesterol<sup>1,32</sup>. *APOE*  $\epsilon 4$  is associated with decreased levels of APOE/triglycerides and with increased levels of APOB/cholesterol<sup>1,32</sup>. *APOE*  $\epsilon 3$  is considered of neutral consequence to blood lipid profiles. These alterations of circulating lipid profiles influence the risk of atherosclerosis based on *APOE* isoform expression.

While *APOE*  $\epsilon 2$  may decrease the risk of AD, it increases the risk of type III hyperlipoproteinemia (HLP) or dysbetalipoproteinemia, a disease which increases the incidence of atherosclerosis<sup>1,33,34</sup>. Patients with type III HLP have high cholesterol, triglycerides, and abnormal accumulation of  $\beta$ -VLDL<sup>1,33</sup>. While all patients with type III HLP are homozygous for *APOE*  $\epsilon 2$ , a large portion of *APOE*  $\epsilon 2$  homozygotes (~90%) do not develop this disease. There are likely other contributing factors beyond *APOE* genotype which contribute to the onset of type III HLP<sup>1,33</sup>.




**Figure 1** APOE lipid transport across diverse tissues. APOE is secreted from the liver with VLDL, cholesterol, and bile acids. In the small intestine, APOE is combined with chylomicrons (CM) and released with VLDL/APOE particles. In capillaries, lipoprotein lipase releases APOE from free fatty acids (FFA) for distribution to peripheral cells. CM/APOE particles are transported to the liver where LDLR releases FFA and cholesterol into the liver. Figure created with Biorender.com.

*APOE*  $\epsilon 4$  genotype places individuals at an increased risk of heart disease<sup>20,32,35–38</sup>. This is likely due to the association of *APOE*  $\epsilon 4$  with elevated LDL and APOB<sup>1</sup>. *APOE*  $\epsilon 4$  binding to VLDL decreases its lipolytic processing which contributes to changes in lipid profiles<sup>1</sup>. APOE does play a role in atherosclerosis as *ApoE* knockout mice have severe atherosclerotic lesions with high lipid levels (including  $\beta$ -VLDL)<sup>39,40</sup>. Macrophages likely play a large role in atherosclerosis. Mice lacking *ApoE* in macrophages are more susceptible, while mice expressing *ApoE* only in macrophages are protected from atherosclerosis<sup>41,42</sup>.

APOE functions in lipid metabolism across many tissue and cell types while also influencing disease risk for atherosclerosis, heart disease, type III HLP, and AD. Evidence is emerging that systemic effects of APOE may affect AD risk<sup>43–45</sup>. For example, heart disease and atherosclerosis are risk factors for AD and cognitive decline in aging. However, APOE mediates direct effects within the brain, and these are discussed below.

### 3. APOE and the brain

APOE is expressed in astrocytes, choroid plexus cells, microglia, and vascular mural cells<sup>5</sup>. Numerous studies cite expression of APOE in stressed neurons<sup>46–51</sup>. APOE binds neuronal low density lipoprotein receptors (LDLRs) including LRP1 to transfer lipids into neurons from surrounding cells. APOE lipid transport between neurons and astrocytes is illustrated in Fig. 2. Peripheral APOE impacts brain health. *ApoE* null mice have synaptic



**Figure 2** APOE lipid transport between neurons and astrocytes. APOE is secreted from astrocytes and then lipidated by ABCA1 or ABCG1. Lipidated APOE is carried to neurons where receptors (LDLR, VLDLR, LRP, or ApoER2) remove APOE from the lipids to release FFA into neurons. Figure created with Biorender.com.

dysfunction, and this can be improved by restoring peripheral *ApoE* expression<sup>52</sup>.

In healthy individuals which are *APOE*  $\epsilon 3/\epsilon 4$  carriers, the ratio of *APOE*  $\epsilon 4$  to *APOE*  $\epsilon 3$  in plasma correlates with loss of gray matter volume and abnormal glucose metabolism. *APOE*  $\epsilon 4$  is associated with increased cortical atrophy and decreased gray matter volume in those with AD<sup>53–55</sup>. Overall, *APOE* isoforms affect lipid transport, glucose metabolism, mitochondrial function, synaptic plasticity,  $A\beta$ , tau, and cerebrovascular function within the brain.

*APOE*  $\epsilon 4$  is the greatest genetic risk factor for late onset AD (LOAD)<sup>1,20</sup>. *APOE*  $\epsilon 4$  also influences risk and outcomes for stroke, traumatic brain injury (TBI), multiple sclerosis (MS), Parkinson's disease (PD), and frontotemporal dementia (FTD) in some studies<sup>55–67</sup>. AD is defined by cognitive decline, memory loss, and postmortem extracellular  $A\beta$  plaques and intracellular neurofibrillary tangles (NFTs). AD subjects show decreased cerebral glucose metabolism, mitochondrial dysfunction, neuroinflammation, loss of proteostasis, vascular changes, and insulin resistance<sup>68–71</sup>. These findings are not unique to the brain in AD subjects as they are also observed in the periphery<sup>72</sup>. *APOE* influences these facets of AD pathology as discussed below and highlighted in Fig. 3.

### 3.1. $A\beta$

$A\beta$  is generated from sequential proteolysis of amyloid precursor protein (APP). APP is cleaved through two pathways, non-amyloidogenic and amyloidogenic. In the nonamyloidogenic

pathway, APP is cleaved by  $\alpha$ -secretase into a C-terminal fragment of 83 amino acid length (C83) and soluble APP  $\alpha$  (sAPP $\alpha$ ). The C83 fragment is trimmed by  $\gamma$ -secretase to form the APP intracellular domain (AICD) and p3 fragments. In the amyloidogenic pathway, APP is cleaved by  $\beta$ -secretase into a C-terminal fragment of 99 amino acid length (C99). The C99 fragment is trimmed by  $\gamma$ -secretase to form the APP intracellular domain (AICD) and  $A\beta$  fragments. These pathways have been reviewed elsewhere<sup>73</sup>. The process of  $A\beta$  generation is understood but the underlying reason for the shift to favor amyloidogenic APP processing in AD is not understood<sup>74</sup>.


*APOE*  $\epsilon 4$  is associated with increased brain  $A\beta$  pathology in a gene dosage dependent manner. Homozygous *APOE*  $\epsilon 4$  carriers have the highest  $A\beta$  pathology burden compared to heterozygous carriers<sup>62,75–77</sup>. *APOE*  $\epsilon 4$  influences  $A\beta$  pathology through increasing its accumulation within brain, development of oligomeric species, and plaque formation<sup>78</sup>. *APOE* binds  $A\beta$  directly, and *APOE*  $\epsilon 4$  binds more efficiently than *APOE*  $\epsilon 3$ <sup>79</sup>. Despite disease status carrying an *APOE*  $\epsilon 4$  allele is associated with increased brain fibrillar  $A\beta$  levels<sup>80</sup>. Deposition of brain  $A\beta$  over time appears to be higher in those that carry an *APOE*  $\epsilon 4$  allele<sup>81,82</sup>. Those who are heterozygous  $\epsilon 2/\epsilon 4$  do not gain protection from the  $\epsilon 2$  allele, as when compared to  $\epsilon 3/\epsilon 4$  individuals, there were no differences in brain  $A\beta$  burden<sup>83</sup>. These studies suggest a strong relationship between *APOE*  $\epsilon 4$  isoforms and  $A\beta$  burden.

Decreased  $A\beta$  clearance could be an underlying mechanism for increased brain  $A\beta$  accumulation in *APOE*  $\epsilon 4$  carriers<sup>84–88</sup>. *APOE*  $\epsilon 4$  has been shown to reduce  $A\beta$  clearance<sup>87,89</sup>.  $A\beta$  is cleared from the brain through interstitial fluid, the blood–brain barrier (BBB), or cellular/enzymatic degradation<sup>90</sup>. *In vivo* and *in vitro* evidence show that *APOE* mediates  $A\beta$  transport through the BBB. *APOE*  $\epsilon 4$  binds preferentially to VLDL (see above) and the VLDL receptor has a slower clearance rate of *APOE*/ $A\beta$  complexes compared to other receptors (LRP1) bound by other *APOE* isoforms<sup>85</sup>. Further studies have examined the specific portions of *APOE* responsible for  $A\beta$  clearance. A truncated *APOE*  $\epsilon 4$  protein missing amino acids 166–299 showed reduced  $A\beta$  clearance, suggesting this is the critical region facilitating  $A\beta$  clearance<sup>91</sup>.

*APOE*  $\epsilon 4$  also decreases cellular uptake and enzymatic degradation of  $A\beta$ . *In vitro* and *in vivo* experiments have shown that astrocytes from *APOE*  $\epsilon 4$  human carriers (or mice) have impaired uptake of  $A\beta$ <sup>92,93</sup>. Other studies suggest *APOE* does not play a critical role in astrocyte  $A\beta$  clearance but LRP1 does. This suggests *APOE* could exhibit competitive binding of LRP1 with  $A\beta$ <sup>87,94</sup>. In microglia, *APOE* mediated cholesterol efflux mediates delivery of  $A\beta$  to lysosomes, and microglia harboring an *APOE*  $\epsilon 4$  allele have reduced  $A\beta$  clearance. Stem cell-derived microglia carrying *APOE*  $\epsilon 4$  alleles show reduced  $A\beta$  phagocytosis when compared to those carrying *APOE*  $\epsilon 3$  alleles<sup>95</sup>. Overall, *APOE*  $\epsilon 4$  appears to impart effects on  $A\beta$  clearance pathways across multiple cell types.

$A\beta$  clearance can also occur through enzymatic degradation by neprilysin and insulin degrading enzyme (IDE). *APOE*  $\epsilon 4$  carriers show decreased expression of these enzymes. In postmortem human brain samples,  $\epsilon 4$  carriers had decreased expression of neprilysin and IDE<sup>96–98</sup>. *APOE*  $\epsilon 4$  may affect neprilysin mediated  $A\beta$  degradation in microglia specifically<sup>95</sup>. Overall, the mechanism and link of *APOE* isoforms to function of these enzymes requires further research.

A final mechanism for  $A\beta$  clearance is through the perivascular system. Mouse studies suggest a role for *APOE*  $\epsilon 4$  in reducing



**Figure 3** *APOE* effects on  $A\beta$ , tau, and neuroinflammation. (A) *APOE*  $\epsilon 4$  increases  $A\beta$  and plaque formation, reduces  $A\beta$  clearance through the blood–brain barrier (BBB), and reduces  $A\beta$  phagocytosis by glia. (B) *APOE*  $\epsilon 4$  increases tau phosphorylation (p-Tau) which increases neurofibrillary tangle (NFT) formation. (C) *APOE*  $\epsilon 4$  increases reactive gliosis and neuroinflammation which can lead to a disrupted BBB. Figure created with Biorender.com.

perivascular drainage of A $\beta$ <sup>99</sup>. Other clearance pathways are less studied, including the glymphatic system. APOE is delivered from the glymphatic system into the brain and the rate of this transport is affected by APOE isoforms<sup>100</sup>. Overall, this topic deserves more attention in the AD field.

The evidence that APOE affects A $\beta$  fibril formation/seedling/oligomerization is weak. Most *in vitro* studies are inconsistent<sup>70</sup>. However, studies implicate that APOE  $\epsilon$ 4 induces A $\beta$  fibrilization more rapidly than APOE  $\epsilon$ 3<sup>101</sup>. *In vivo* studies suggest that reduction of APOE levels in astrocytes before A $\beta$  fibrils are formed reduces A $\beta$  pathology<sup>102</sup>. However, this mechanism does not have an effect after A $\beta$  fibrils are formed. Expression of APOE  $\epsilon$ 4 in astrocytes of mice was found to increase A $\beta$  pathology when compared to APOE  $\epsilon$ 3 isoform expression<sup>90,103</sup>.

A $\beta$  biology is also affected by expression levels of APP. *In vitro* studies suggest APOE increases the transcription of APP. Separate studies show that APOE  $\epsilon$ 4 increases A $\beta$  production in stem cell-derived neurons<sup>92,104</sup>. *In vivo* studies have failed to replicate *in vitro* findings. Mice with humanized APOE show no change in A $\beta$  production between APOE isoforms<sup>105</sup>. However, there are concerns regarding the relevance of humanized APOE mouse models and the effects of mouse receptors interacting with human proteins.

### 3.2. Tau

Tau pathology is observed in AD and other neurodegenerative diseases (known as tauopathies). In AD, tau forms insoluble intercellular NFTs. Tau hyperphosphorylation has been shown to decrease the solubility of tau and promote tangle formation. Tau biology and pathology have been extensively reviewed elsewhere<sup>106,107</sup>. APOE  $\epsilon$ 4 interacts with tau pathology in AD.

Postmortem studies indicated that homozygous APOE  $\epsilon$ 4 carriers have higher tau pathology than heterozygotes or non-carriers<sup>77,108–110</sup>. *In vivo* studies show that neuronal expression of APOE  $\epsilon$ 4 increases tau hyperphosphorylation<sup>111</sup>. This could increase NFT formation. Stem cell-derived cerebral organoids from APOE  $\epsilon$ 4 carriers have higher tau phosphorylation when compared to APOE  $\epsilon$ 3 carrier-derived models<sup>112</sup>. Humanized APOE mice expressing mutant tau (P301S) show increased brain atrophy and neuroinflammation with APOE  $\epsilon$ 4 expression<sup>113</sup>. Other studies have shown increased tau pathology in mice harboring human APOE  $\epsilon$ 2 alleles when compared to other isoforms<sup>114</sup>.

Fragments of APOE have effects on tau biology and pathology. C-terminal truncated forms of APOE  $\epsilon$ 3 and  $\epsilon$ 4, bearing amino acids 1–271 were shown to interact with phosphorylated tau species<sup>115</sup>. Truncated APOE  $\epsilon$ 4 was more likely to interact and induce NFT formation than truncated APOE  $\epsilon$ 3. APOE residues 245–260 are critical for the tau interaction and NFT formation<sup>116</sup>. In transgenic mice expressing neuron specific APOE  $\epsilon$ 3 or  $\epsilon$ 4, C-terminal truncated APOE products were observed<sup>46</sup>. These C-terminal APOE products were more prominent with APOE  $\epsilon$ 4 expression and with age, the APOE truncation patterns were like observations in human brain<sup>46</sup>. In mice expressing astrocyte specific APOE isoforms, no C-terminal APOE fragments were detected in brain tissue. The neuron specific APOE  $\epsilon$ 4 mice showed increased phosphorylated tau and intraneuronal tau inclusions when compared to APOE  $\epsilon$ 3 mice. These effects on tau were not observed when APOE expression was restricted to astrocytes<sup>116</sup>. C-terminal truncated APOE fragments (1–272) from AD brain samples induce NFTs in neuronal cultures. These C-

terminal fragments are more likely to be generated from APOE  $\epsilon$ 4 isoforms than APOE  $\epsilon$ 3<sup>116</sup>.

The effects of APOE isoforms on tau biology and the interaction between the two are apparent. A link between tau, A $\beta$ , and neuroinflammation is evident and discussed below.

### 3.3. Neuroinflammation

APOE has a role in innate immunity. Glial cells, or microglia and astrocytes, are the main innate immunity components within the brain. Microglia respond to damage and pathogen associated molecular patterns in addition to other functions, such as synaptic pruning<sup>117</sup>. Microglial response can be attributed to repair or pro-inflammatory functions. Astrocytes are phagocytic like microglia, but also support neurons metabolically through interactions between neurons and vascular components<sup>117</sup>. Aberrant astrocyte and microglia phenotypes are observed in AD and are referred to disease associated phenotypes<sup>117</sup>. Astrocytes are the main APOE expressing cell type within the brain, however microglia also express APOE<sup>117</sup>.

Microglia upregulate APOE expression in response to amyloid and tau pathologies. APOE  $\epsilon$ 4 likely increases the microglial proinflammatory phenotype in transgenic tau mice. APOE binds to triggering receptor on myeloid cells 2 (TREM2)<sup>118–121</sup>. The R47H TREM2 variant, although rare, is associated with increased AD risk<sup>122–124</sup>. TREM2 functions to downregulate the pro-inflammatory response through clearance of damaged cells or other debris (including A $\beta$ ) by promoting phagocytosis in microglia<sup>125–127</sup>. This function appears to be disrupted in AD<sup>128</sup>. The association of APOE with amyloid plaques is dependent on TREM2 and appears to originate from microglia<sup>129</sup>.

In AD transgenic mice, data show a role for APOE in promoting gliosis. In transgenic mutant APPV717F mice administered chronic LPS APOE promoted gliosis and A $\beta$  deposition<sup>129</sup>. Further *in vivo* studies using humanized APOE mice administered chronic LPS, showed that APOE  $\epsilon$ 4 increased pro-inflammatory cytokine expression when compared to APOE  $\epsilon$ 3<sup>130</sup>. APOE  $\epsilon$ 4 increases nitric oxide (NO) release by microglia in humanized APOE mice and in human microglia<sup>131</sup>. In mice, microglia expressing APOE  $\epsilon$ 4 have increased pro-inflammatory cytokine expression and NO production when compared to APOE  $\epsilon$ 3 expressing microglia<sup>132</sup>. These effects are gene dosage dependent and observed in peripheral macrophages of APOE  $\epsilon$ 4 mice<sup>132</sup>.

APOE is required for inflammatory responses against A $\beta$  and tau. APP<sup>swe</sup>/PSEN1 $\Delta$ E9 and APP<sup>swe</sup>/PSEN1\*LI66P transgenic mice lacking APOE showed reduced A $\beta$  pathology, altered A $\beta$  plaque morphology, but increased size of A $\beta$  plaques<sup>133</sup>. A reduction in microgliosis was also observed especially associated with A $\beta$  plaques. Despite reduced microgliosis in APOE knockout mice, an increase in dystrophic neurites was observed surrounding A $\beta$  plaques<sup>133</sup>. Tau pathology and inflammatory response are also modulated by APOE. In humanized APOE  $\epsilon$ 4 P301S Tau transgenic mice, depletion of microglia resulted in reduced tau pathology<sup>134</sup>. Increasing APOE expression in P301S Tau transgenic mice correlated with increased phosphorylated tau and insoluble tau<sup>134</sup>. Depletion of microglia in APOE  $\epsilon$ 4 humanized P301S Tau transgenic mice decreased brain atrophy<sup>134</sup>. In a separate study using P301S Tau transgenic mice with either humanized APOE or APOE knockout, it was apparent that APOE modulated tau pathology<sup>113</sup>. In humanized APOE  $\epsilon$ 4 mice on the P301S Tau, background higher levels of tau, increased brain atrophy, and neuroinflammation were observed when compared with APOE  $\epsilon$ 2

and APOE  $\epsilon 3$  isoforms<sup>113</sup>. APOE knockout mice appeared protected from these phenotypes. Co-cultures of APOE  $\epsilon 4$  expressing astrocytes with P301S Tau expressing neurons lead to increased pro-inflammatory cytokine expression when compared to other APOE isoforms<sup>113</sup>. These studies highlight the interactions between APOE, A $\beta$ , tau, and neuroinflammatory pathologies.

Certain structural components of APOE are critical for neuroinflammatory modulation. APOE amino acids 1–185 have been shown to regulate levels of matrix metalloproteinase 9 (MMP9) and tissue inhibitor of metalloproteinase 1 (TIMP1)<sup>135</sup>. APOE modulates neuroinflammatory molecules by increasing IL1 $\beta$  and decreasing IL10 levels. Other truncated forms of APOE have been shown to be anti-inflammatory, such as a 133–149 APOE peptide<sup>130</sup>. Overall, more research is needed to understand the structure/function relationship between APOE and neuroinflammation.

The effects of APOE on MMP9 are important not only for neuroinflammation but also BBB integrity<sup>136</sup>. APOE  $\epsilon 4$  is associated with decreased BBB integrity<sup>117</sup>. The tight junctions responsible for maintaining BBB integrity are compromised with APOE  $\epsilon 4$  expression<sup>137</sup>. Pericytes and MMP9 seem to mediate these effects<sup>138</sup>. A separate study using APOE humanized mice showed similar findings, that APOE  $\epsilon 4$  activated a cyclophilin A/NF- $\kappa$ B/MMP9 pathway in pericytes<sup>139</sup>. In the context of other models, APOE has been shown to activate MMP9 and reduce BBB integrity, especially in the context of TBI<sup>140</sup>. APOE modulation of inflammatory pathways appears to also affect BBB integrity and therefore could modulate other AD risk factors like TBI.

### 3.4. Mitochondria and metabolism

Mitochondrial dysfunction and metabolism changes are observed within the brain and periphery in AD subjects. Brain glucose metabolism is decreased as observed through fluorodeoxyglucose positron emission tomography (FDG-PET)<sup>71,141</sup>. Systemic glucose metabolism is altered as insulin resistance and insulin levels are increased in AD<sup>72,142</sup>. An association of type two diabetes and AD risk is apparent<sup>72,142</sup>. Mitochondrial dysfunction is observed across *in vitro* models, *in vivo* models, and human AD subjects. Cytochrome oxidase (COX) or complex IV of the electron transport chain (ETC) has decreased maximum velocity (Vmax)<sup>69,71,143–146</sup>. Mitochondrial number and respiration are lower across models<sup>71</sup>. Mitophagy pathways are aberrant<sup>71,147</sup>. Overall, APOE  $\epsilon 4$  carriers appear to have worse metabolic and mitochondrial function when compared to non-carriers in both healthy and diseased states.


Individuals with APOE  $\epsilon 4$  alleles have reduced brain glucose metabolism and insulin signaling, independent of A $\beta$ <sup>148</sup>. Mice with humanized APOE  $\epsilon 4$  show decreased brain glucose uptake, reduced cerebral blood volume, and impaired insulin signaling<sup>149</sup>. Humanized APOE  $\epsilon 4$  mice show changes in purine, glucose, and pentose-phosphate metabolism<sup>149</sup>. These *in vivo* effects are only observed with advanced age or introduction of a high fat diet. Separate studies show humanized APOE  $\epsilon 4$  mice have metabolic shifts towards lipid oxidation and thermogenesis. These mice also have increased insulin resistance and elevated insulin levels<sup>150</sup>. Overall, changes to brain metabolism appear consistent across human and animal studies.

The APOE receptor, LRP1, might play a critical role in brain glucose metabolism. Deletion of LRP1 in forebrain neurons of mice reduced brain insulin levels and glucose metabolism<sup>151</sup>.

However, some studies suggest APOE itself plays a role in insulin signaling. APOE interacts with insulin receptors and influences their trafficking through endosomes. APOE  $\epsilon 4$  impairs insulin receptor endosome trafficking and signaling *in vitro*<sup>152</sup>. The mechanism of altered brain glucose and insulin signaling with various APOE isoforms requires more study. The effects of APOE isoforms on brain metabolism are also observed within mitochondria as discussed below.

APOE fragments which originate from APOE  $\epsilon 4$  specifically can directly affect mitochondrial function (Fig. 4). An APOE C-terminal fragment (1–272) localizes to mitochondria and induces mitochondrial dysfunction<sup>153</sup>. The 1–272 C-terminal fragment of APOE was shown to bind to components of complex III and complex IV (COX) of the ETC *in vitro* and reduce their activity<sup>153</sup>. Other studies have suggested that APOE  $\epsilon 4$  increases the activity and association of mitochondria with the endoplasmic reticulum (ER), or mitochondrial associated endoplasmic reticulum membranes (MAM) *in vitro*<sup>154</sup>. Expression of a neuronal directed APOE C-terminal fragment 1–272 induced ER stress and the formation of MAMs *in vitro* and *in vivo*. The mechanism of this finding is supported through increased calcium loading of mitochondria through glucose regulated protein 75 (GRP75)<sup>155</sup>. APOE fragments derived from APOE  $\epsilon 4$  specifically localize to mitochondria, alter mitochondrial function, and influence mitochondrial–ER interactions.

Humanized APOE mice expressing APOE  $\epsilon 4$  have lower expression of sirtuin 3 (SIRT3) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 $\alpha$ )<sup>156</sup>. These two proteins are critical for coordinating mitochondrial biogenesis and ultimately lower expression can result in decreased



**Figure 4** APOE effects on mitochondria in neurons. APOE synthesis is stimulated by stress signals in neurons. Synthesis occurs in the endoplasmic reticulum (ER) and if sorted through the Golgi APOE is secreted. Otherwise APOE is cleaved to generate toxic fragments which cause mitochondrial dysfunction. Fragmentation of APOE occurs only with APOE  $\epsilon 4$  isoforms. Figure created with Biorender.com.

mitochondrial mass. *APOE*  $\epsilon 4$  mice also show reduced ATP production, altered NAD/NADH ratios, reduced synaptic markers, and lower cognition<sup>156</sup>. Overall, *APOE*  $\epsilon 4$  mice have altered proteomic profiles of mitochondrial proteins<sup>157</sup>. In astrocytes, *APOE*  $\epsilon 4$  increased mitochondrial fission, reduced autophagy and mitophagy, and reduced ATP levels<sup>158</sup>. Globally *APOE* affects brain metabolism, however some effects could be cell type specific.

In postmortem human brain, *APOE*  $\epsilon 4$  carriers showed changes to expression levels of proteins involved in mitochondrial structure, oxidative stress, and synaptic integrity<sup>159</sup>. The levels of these proteins were correlated with cognitive function within these subjects<sup>159</sup>. Postmortem brain samples from young *APOE*  $\epsilon 4$  carriers (prior to potential AD onset) had reduced COX activity with no changes to  $A\beta$  or tau pathology in the posterior cingulate cortex<sup>160</sup>. Further studies in young *APOE*  $\epsilon 4$  carrier postmortem brain tissue showed changes to metabolic pathway protein expression. Increased glucose and monocarboxylate transporters, hexokinase (glycolysis), ketone metabolism proteins (SCOT and AACs), and ETC enzymes from complex I, II, and IV were observed<sup>161</sup>. Overall, these data suggest a metabolic compensatory mechanism in *APOE*  $\epsilon 4$  carriers decades before AD onset.

Astrocytes play a crucial role in metabolic support in the brain, where they provide lactate, lipids, amino acids, and neurotransmitters to neurons. Disruption of the astrocyte/neuron energy coupling has been a proposed AD pathological mechanism<sup>162</sup>. Astrocytes expressing *APOE*  $\epsilon 4$  when compared to  $\epsilon 2$  and  $\epsilon 3$  have impaired glucose uptake, with specific deficits in early glycolysis but increased lactate production<sup>163</sup>. *APOE*  $\epsilon 4$  in astrocytes increased flux through the pentose phosphate pathway, gluconeogenesis, lipid, and nucleotide biosynthesis. Astrocytes with *APOE*  $\epsilon 4$  likely increase carbon flux through the tricarboxylic acid (TCA) cycle leading to cataplerosis, as compared to increased oxidation and anaplerosis in  $\epsilon 2$  and  $\epsilon 3$  expressing astrocytes<sup>163</sup>. These findings suggest an overall energy deficit in astrocytes expressing *APOE*  $\epsilon 4$  and are consistent with studies completed in peripheral cell types as discussed below.

*APOE* genotype effects blood-based measures of mitochondrial function and neuroinflammation<sup>164</sup>. *APOE*  $\epsilon 4$  carriers have decreased mitochondrial COX Vmax in platelets from blood compared to non-carriers<sup>164,165</sup>. These studies utilized only AD patients to control for potential confounding factors related to AD medications on mitochondrial function. Lymphocytes from AD *APOE*  $\epsilon 4$  carriers showed increased expression of inflammatory pathways and altered bioenergetic pathways suggesting an energy stress response<sup>164</sup>. Overall, *APOE*  $\epsilon 4$  expression results in an energy deprivation/starvation state in numerous cell types.

### 3.5. Synaptic function and axonal repair

*APOE* may play a role in axonal repair through the redistribution of lipids to Schwann cells for remyelination<sup>1,166–170</sup>. *APOE*  $\epsilon 4$  may impair neurite outgrowth. *APOE*  $\epsilon 4$  destabilizes microtubules and increases NFT formation through tau hyperphosphorylation<sup>1,108,171,172</sup>. *In vitro* studies show that *APOE*  $\epsilon 4$  alters cytoskeleton structure and impairs neurite outgrowth when compared to *APOE*  $\epsilon 3$ <sup>173–175</sup>. While more recent studies in new models are lacking, nonetheless these findings are of interest to the AD field.

Further studies have focused on the mechanism of *APOE* effects on memory and neurite outgrowth. Humanized *APOE* mice expressing *APOE*  $\epsilon 2$ ,  $\epsilon 3$ , or  $\epsilon 4$  were crossed with humanized

*LDLR* or *LDLR* knockout mice. *LDLR* knockout mice and humanized *LDLR/APOE*  $\epsilon 4$  mice showed spatial memory deficits<sup>176</sup>. LRP appears to mediate the effects of *APOE* on neurite outgrowth. *APOE*  $\epsilon 3$  associated  $\beta$ -VLDL and HDL particles stimulate neurite outgrowth more efficiently than those containing *APOE*  $\epsilon 4$  *in vitro*<sup>177,178</sup>. *APOE* containing lipid particles act as a ligand for LRP *in vitro*<sup>177,178</sup>. Overall, *APOE* appears to affect neurite outgrowth *in vitro* and *in vivo* through an LRP mediated mechanism.

The effects of *APOE* on synaptic function and memory are also attributed to effects on neurotransmitter receptor expression and recycling. *APOE*  $\epsilon 4$  reduces neurotransmitter receptor expression, including *N*-methyl-D-aspartate (NMDA) and  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. The mechanism of this is likely through effects on receptor trafficking resulting in impaired synaptic function<sup>179</sup>. NMDA receptor function is also affected by its phosphorylation through Reelin. *APOE*  $\epsilon 4$  reduces the expression of a receptor for both *APOE* and Reelin (apolipoprotein E receptor 2 or ApoER2). The reduced expression of ApoER2 and the reduced cell trafficking of NMDA/AMPA receptors leads to reduction of long-term potentiation (LTP) and reduced synaptic function<sup>179</sup>. In humanized *APOE* mice, *APOE*  $\epsilon 4$  appeared to increase LTP in the hippocampus through NMDA receptors<sup>180</sup>. While acute exposure of hippocampal slices to *APOE*  $\epsilon 4$  reduced LTP through NMDA receptors<sup>180</sup>. A separate study using hippocampal slices from humanized *APOE* mice showed reduced LTP in *APOE*  $\epsilon 4$  expressing slices<sup>181</sup>. Overall, the *in vivo* effects are not consistent but *APOE* appears to influence synaptic function through NMDA receptors.

### 3.6. Sex specific effects of *APOE* in AD

The prevalence of LOAD is higher in females even when adjusted for age and lifespan sex differences<sup>182,183</sup>. Females with MCI and LOAD have higher rates of disease progression and higher burden of neuropathology (such as  $A\beta$  and tau)<sup>184,185</sup>. Female heterozygote *APOE*  $\epsilon 4$  carriers show similar AD risk to male homozygous *APOE*  $\epsilon 4$  carriers<sup>186,187</sup>. Menopause or loss of estrogen was thought to play a role in the increased risk of LOAD and *APOE*  $\epsilon 4$  associated LOAD in females<sup>187</sup>.

*APOE*  $\epsilon 4$  alleles have been shown to influence the onset of menopause<sup>188,189</sup>. *APOE*  $\epsilon 4$  increases the perimenopause period which leads to reduced glucose metabolism<sup>187</sup>. *APOE*  $\epsilon 4$  also reduces the protective effects of estrogen and can worsen the effects of the loss of sex hormones during menopause<sup>187</sup>. Some studies suggest that the energy shift towards ketosis during menopause leads to reductions in white matter and loss of myelination in *APOE*  $\epsilon 4$  carriers<sup>190–192</sup>. These studies have been replicated in ovariectomy transgenic AD mouse models<sup>193,194</sup>.

Both *APOE* and estrogen are important for cholesterol metabolism. While *APOE* is discussed above, estrogen regulates cholesterol synthesis and transport, through LRP1, *LDLR*, and hydroxymethylglutaryl-CoA reductase (HMG-CR)<sup>195,196</sup>. *APOE* also appears to control hormone levels during menopause including estradiol. Other studies show that estradiol mediates *APOE* expression and neuroprotective effects<sup>187</sup>. *In vitro* and *in vivo* studies show that estrogen can increase *APOE* expression<sup>197,198</sup>.

Female rodents do not undergo menopause but do have reduced levels of estrogen during aging<sup>187,199</sup>. As such AD associated changes are more pronounced in female AD

transgenic mice than male mice<sup>187</sup>. Humanized *APOE*  $\epsilon 4$  female mice show worse cognition than males<sup>200</sup>. A recent study compared female humanized *APOE*  $\epsilon 4$  mice with samples from human plasma<sup>201</sup>. It was found that in mice *APOE*  $\epsilon 4$  is associated with reduced oxidative phosphorylation and increased glycolysis in astrocytes suggesting a shift towards aerobic glycolysis<sup>201</sup>. Human plasma samples and indirect calorimetry measures supported the data found in mice<sup>201</sup>. Overall, more research needs to focus on sex differences in AD, especially with regards to *APOE*  $\epsilon 4$ .

#### 4. APOE specific therapeutic development in AD

Therapeutic approaches targeting APOE directly focus on genome editing, antisense oligonucleotides, modulators of APOE structure and interactions, antibodies against APOE, and efforts to alter the lipidation levels of APOE<sup>202,203</sup>. Other therapeutic efforts are indirect and focus on modulating lipid levels and energy metabolism through changes to life-style factors. The method of therapeutic targeting for APOE in AD is dependent on the mechanism of how APOE modulates risk. Some therapeutic strategies assume *APOE*  $\epsilon 4$  results in a gain of toxic function and others assume a loss of function consequence. These therapeutic approaches are reviewed below.

Several therapeutic approaches aim to change the expression levels and direct receptor interactions of APOE using distinct mechanisms. One approach is to treat with antisense oligonucleotides to disrupt APOE or receptor protein synthesis and expression levels. This therapeutic approach has only been examined in animal models to date. However, in AD transgenic mice antisense oligonucleotides targeting *Apoer2* improved synaptic function and cognition<sup>204</sup>. Antisense oligonucleotides against *APOE* reduce A $\beta$  burden in AD transgenic mice<sup>103</sup>. Small molecules which modulate APOE and receptor expression have been tested in animal models and clinical trials. GW3965 increases APOE and ABCA1 expression levels and shows cognitive benefit with reduced A $\beta$  in AD transgenic mice<sup>205</sup>. Bexarotene is an RXR agonist that modulates APOE expression and has showed varying results in AD mouse models<sup>202,206</sup>. In one study, Bexarotene reduced A $\beta$  pathology in AD transgenic mice but several other studies failed to replicate these findings. In one clinical trial (BEAT-AD), Bexarotene failed to show any cognitive benefit but did reduce A $\beta$  levels in AD subjects<sup>207</sup>. In healthy subjects, Bexarotene increased APOE levels but did not affect A $\beta$  within the central nervous system (CNS)<sup>208</sup>. Furthermore, side effects of Bexarotene include increased risk of stroke and cardiovascular disease due to altered lipid homeostasis and further studies suggest that the drug has low CNS penetrance<sup>202</sup>. Overall, antisense oligonucleotides may prove to have reduced side effects and better CNS penetrance when compared to small molecule modulators.

*APOE*  $\epsilon 4$  is hypo-lipidated due to its domain–domain interactions and salt bridge between the C- and N-terminus. This structural feature reduces *APOE*  $\epsilon 4$  lipid interactions. One therapeutic approach is to increase the lipidation of APOE using the small molecule CS-6253<sup>209</sup>. This small peptide molecule activates ABCA1 and increases APOE lipidation in AD mouse models while also reducing A $\beta$ /tau pathologies and increasing cognitive function<sup>209</sup>. Antisense oligonucleotides targeting microRNAs (miRNA) which reduce ABCA1 expression have been tested *in vivo* and *in vitro* where they reduce A $\beta$ <sup>210,211</sup>. Other peptide mimetics have been shown to alter the lipidation of APOE while also increasing its

secretion. 4F binds to LDL and HDL and is an 18 amino acid peptide. *In vitro* 4F increases APOE lipidation and secretion but no other studies have examined its effects in AD models<sup>212</sup>. Other mimetics, COG112 and COG113, showed beneficial effects in both *Drosophila* and mouse models of AD<sup>132,213,214</sup>. CN-105 is an APOE mimetic that has been tested in a clinical trial for intracerebral hemorrhage (ICH) and showed beneficial effects on neuroinflammation in mouse models<sup>215</sup>. In the phase I trial, CN-105 showed safety, tolerability, and reduced disability in a small cohort of patients with ICH<sup>216</sup>. Overall, clinical trials are lacking in AD for targeting APOE lipidation as a therapeutic target.

Targeting the domain–domain interaction of APOE  $\epsilon 4$  has been tested in AD animal models. This approach uses small molecules identified in high-throughput screening approaches and was shown to stabilize APOE  $\epsilon 4$ . Two small molecules (CB9032258 and PH-002) restore COX levels within the mitochondria and mitochondrial function while inhibiting the APOE  $\epsilon 4$  domain interaction *in vitro*<sup>217</sup>. One additional *in vitro* study showed PH-002 reduced APOE fragmentation and reduced A $\beta$  and tau pathologies<sup>104</sup>. However, no *in vivo* studies have followed up on these findings to date.

Antibodies targeting APOE have shown positive effects in AD animal models but have not been tested in the clinic. In AD transgenic mice, APOE targeted antibodies reduced A $\beta$  plaques, improved cognition, and did not affect plasma cholesterol levels<sup>218,219</sup>. In one study, administration of APOE antibodies after A $\beta$  plaque formation showed beneficial effects in a transgenic AD mouse model<sup>219</sup>. Other antibody therapies (HAE-4) target non-lipidated forms of APOE regardless of isoform. HAE-4 showed beneficial effects in a transgenic mouse model harboring both mutant *APP* and *APOE*  $\epsilon 4$ . HAE-4 reduced A $\beta$  pathology and was able to do so efficiently when administered systemically<sup>220</sup>. Thus far, no clinical trials examining the effects of APOE targeted antibodies are ongoing.

Genetic engineering approaches to modulate APOE expression and function include viral mediated gene transfer and CRISPR/Cas9 gene editing. The overall goal with this strategy is to modify the *APOE*  $\epsilon 4$  alleles to *APOE*  $\epsilon 3$  or  $\epsilon 2$ . CRISPR genome editing has been completed *in vitro* but not using *in vivo* models<sup>92,221</sup>. Adenoviral mediated delivery (AAV) of *APOE*  $\epsilon 2$  is currently enrolling an open label phase I clinical trial with expected completion in 2023. The goal of the study is to test the safety and toxicity of intracisternal administration of an AAV gene transfer vector expressing human *APOE*  $\epsilon 2$ . Intracisternal injection allows direct delivery of the AAV vector into the cerebrospinal fluid (CSF) and the intended population for the phase I trial are homozygous *APOE*  $\epsilon 4$  carriers with AD ([ClinicalTrials.gov](https://clinicaltrials.gov); Identifier: NCT03634007). Injection of AAV-*APOE*  $\epsilon 2$  into AD transgenic mouse models did reduce A $\beta$  burden and is the basis for the phase I clinical trial<sup>222</sup>.

Changes to lifestyle factors can indirectly target the effects of *APOE*  $\epsilon 4$  on AD risk. These lifestyle changes include diet and exercise. The beneficial effects of exercise on the brain and in AD models have been established and reviewed elsewhere<sup>72,223–229</sup>. Human clinical trial results are mixed but overall, the amount and type of exercise that is beneficial in AD needs to be established. Numerous clinical trials are currently enrolling with the goal to examine the type and regimen of exercise most beneficial in AD. A search of [ClinicalTrials.gov](https://clinicaltrials.gov) yields 65 currently enrolling studies focused on exercise in AD. Diet modifications which are targeted for AD and *APOE*  $\epsilon 4$  include the ketogenic and Mediterranean



diets, both of which show beneficial effects in AD mouse models. Four trials are currently enrolling for the ketogenic diet and three for the Mediterranean diet. The overall goal with diet and exercise modifications are to alter energy homeostasis by providing alternative fuel sources for the brain with added benefit of modulating lipid profiles and insulin resistance.

## 5. Concluding remarks

While APOE was originally identified as a lipid binding protein, its effects are pleiotropic. Polymorphisms in *APOE* modulate risk for vascular disease and AD. There are likely other unidentified associations of *APOE* isoforms with diseases across lifespan. It's also important to note that some *APOE* isoforms confer advantages early in life but are a disadvantage in aging. The role of *APOE* in the brain has largely focused on the effects of *APOE*  $\epsilon 4$ . While APOE is mostly expressed in glial cells (astrocytes and microglia), its effects are observed on other cell types, including neurons.

APOE  $\epsilon 4$  influences pathologies observed in AD. APOE  $\epsilon 4$  is associated with increased A $\beta$  burden likely through reducing its clearance and degradation. Tau hyperphosphorylation and NFTs are increased in the presence of APOE  $\epsilon 4$ . Not surprisingly, APOE  $\epsilon 4$  modulates neuroinflammation and this role directly impacts its effects on A $\beta$  and tau pathologies. Mitochondrial function and metabolism are altered by the expression of APOE  $\epsilon 4$ , and these effects are observed in the periphery as well as the brain. Overall, the effects of APOE  $\epsilon 4$  on AD associated pathologies are clear.

Therapeutic development targeting APOE in AD has focused thus far on mouse and cell models of disease. A critical issue is a lack of understanding of the disease modifying factor which leads to increased risk of AD with *APOE*  $\epsilon 4$ . Without this basic understanding, therapeutic strategies are difficult and rely on assumptions of gain or loss of function approaches.

An important question for the AD field remains, are the effects of APOE  $\epsilon 4$  on AD pathologies a cause or effect? Of particular interest is the need to understand the role of metabolic deficits caused by APOE  $\epsilon 4$  expression in driving AD pathology. Addressing this mechanistic question can drive therapeutic development.

## Acknowledgments

This work was supported by the National Institutes of Health (P30AG035982 and R00AG056600, USA) and the Peg McLaughlin fund (USA).

## Author contributions

Benjamin R. Troutwine, Laylan Hamid, Colton R. Lysaker, Taylor A. Strobe, and Heather M. Wilkins contributed to writing and editing the article.

## Conflicts of interest

The authors declare that they have no competing interests or conflicts.

## References

- Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid. *Annu Rev Genom Hum Genet* 2000;1:507–37.
- Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E—a multifunctional protein with implications in various pathologies as a result of its structural features. *Comput Struct Biotechnol J* 2017;15:359–65.
- Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. *Nature* 1977;269:604–7.
- Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. *Proc Natl Acad Sci U S A* 2011;108:14813–8.
- Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. *Biochim Biophys Acta* 1987;917:148–61.
- Huebbe P, Rimbach G. Evolution of human apolipoprotein E (APOE) isoforms: gene structure, protein function and interaction with dietary factors. *Ageing Res Rev* 2017;37:146–61.
- McIntosh AM, Bennett C, Dickson D, Anestis SF, Watts DP, Webster TH, et al. The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes). *PLoS One* 2012;7:e47760.
- Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengard JM, et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. *Am J Hum Genet* 2000;67:881–900.
- Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. *Ann Hum Biol* 2006;33:279–308.
- Egert S, Rimbach G, Huebbe P. ApoE genotype: from geographic distribution to function and responsiveness to dietary factors. *Proc Nutr Soc* 2012;71:410–24.
- Hu P, Qin YH, Jing CX, Lu L, Hu B, Du PF. Does the geographical gradient of ApoE4 allele exist in China? A systemic comparison among multiple Chinese populations. *Mol Biol Rep* 2011;38:489–94.
- Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* 1997;278:1349–56.
- Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele  $\epsilon 4$  with late-onset familial and sporadic Alzheimer's disease. *Neurology* 1993;43:1467–72.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci U S A* 1993;90:1977–81.
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 1993;261:921–3.
- Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ, et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. *J Lipid Res* 1982;23:911–4.
- Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. *Biochemistry* 1981;20:1033–41.
- Wernette-Hammond ME, Lauer SJ, Corsini A, Walker D, Taylor JM, Rall Jr SC. Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. *J Biol Chem* 1989;264:9094–101.
- Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 1988;240:622–30.
- Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. *Curr Opin Lipidol* 1999;10:207–17.

21. Weisgraber KH. Apolipoprotein E: structure–function relationships. *Adv Protein Chem* 1994;**45**:249–302.
22. Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimer's disease connection. *FASEB J* 1996;**10**:1485–94.
23. Schneider WJ, Kovanan PT, Brown MS, Goldstein JL, Utermann G, Weber W, et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. *J Clin Invest* 1981;**68**:1075–85.
24. Mahley RW, Innerarity TL. Lipoprotein receptors and cholesterol homeostasis. *Biochim Biophys Acta* 1983;**737**:197–222.
25. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. *J Lipid Res* 1999;**40**:1–16.
26. Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. *J Lipid Res* 2009;**50** Suppl:S156–61.
27. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. *J Biol Chem* 2004;**279**:40987–93.
28. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. *Neuron* 2001;**29**:571–81.
29. Herz J, Willnow TE. Functions of the LDL receptor gene family. *Ann N Y Acad Sci* 1994;**737**:14–9.
30. Cooper AD. Hepatic uptake of chylomicron remnants. *J Lipid Res* 1997;**38**:2173–92.
31. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. *J Clin Invest* 2006;**116**:1226–9.
32. Zende PD, Bankar MP, Kamble PS, Momin AA. Apolipoprotein E gene polymorphism and its effect on plasma lipids in arteriosclerosis. *J Clin Diagn Res* 2013;**7**:2149–52.
33. Mahley RW, Huang Y, Rall Jr SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. *J Lipid Res* 1999;**40**:1933–49.
34. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins—an integrated approach to mechanisms and disorders. *N Engl J Med* 1967;**276**:273–81.
35. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis* 1988;**8**:1–21.
36. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. *Am J Epidemiol* 2002;**155**:487–95.
37. Menzel HJ, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. *Arteriosclerosis* 1983;**3**:310–5.
38. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. *Circulation* 1995;**91**:265–9.
39. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. *Arterioscler Thromb* 1994;**14**:133–40.
40. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesion development and progression. *Arterioscler Thromb* 1994;**14**:141–7.
41. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. *J Clin Invest* 1995;**96**:2170–9.
42. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. *Proc Natl Acad Sci U S A* 1997;**94**:4647–52.
43. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, et al. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. *Arterioscler Thromb Vasc Biol* 2003;**23**:2055–62.
44. de Bruijn RF, Ikram MA. Cardiovascular risk factors and future risk of Alzheimer's disease. *BMC Med* 2014;**12**:130.
45. Eriksson UK, Bennet AM, Gatz M, Dickman PW, Pedersen NL. Nonstroke cardiovascular disease and risk of Alzheimer disease and dementia. *Alzheimer Dis Assoc Disord* 2010;**24**:213–9.
46. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, et al. Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. *J Neurosci* 2004;**24**:2527–34.
47. Butterfield DA, Mattson MP. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease. *Neurobiol Dis* 2020;**138**:104795.
48. Dekroon RM, Armati PJ. Synthesis and processing of apolipoprotein E in human brain cultures. *Glia* 2001;**33**:298–305.
49. Harris FM, Tesseur I, Brecht WJ, Xu Q, Mullendorff K, Chang S, et al. Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. *J Biol Chem* 2004;**279**:3862–8.
50. Horsburgh K, McCulloch J, Nilsen M, Roses AD, Nicoll JA. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. *Eur J Neurosci* 2000;**12**:4309–17.
51. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the *ApoE* locus. *J Neurosci* 2006;**26**:4985–94.
52. Lane-Donovan C, Wong WM, Durakoglugil MS, Wasser CR, Jiang S, Xian X, et al. Genetic restoration of plasma ApoE improves cognition and partially restores synaptic defects in *ApoE*-deficient mice. *J Neurosci* 2016;**36**:10141–50.
53. Filippini N, Rao A, Wetten S, Gibson RA, Borrie M, Guzman D, et al. Anatomically-distinct genetic associations of *APOE*  $\epsilon 4$  allele load with regional cortical atrophy in Alzheimer's disease. *Neuroimage* 2009;**44**:724–8.
54. Boccardi M, Sabatoli F, Testa C, Beltramello A, Soininen H, Frisoni GB. APOE and modulation of Alzheimer's and frontotemporal dementia. *Neurosci Lett* 2004;**356**:167–70.
55. Agosta F, Vessel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, et al. Apolipoprotein E  $\epsilon 4$  is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. *Proc Natl Acad Sci U S A* 2009;**106**:2018–22.
56. Becker KG. APOE genotype is a major predictor of long-term progression of disability in MS. *Neurology* 2001;**57**:2148–9.
57. Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, et al. Apolipoprotein E  $\epsilon 4$  is associated with rapid progression of multiple sclerosis. *Neurology* 2001;**57**:853–7.
58. Savettieri G, Andreoli V, Bonavita S, Cittadella R, Caltagirone C, Fazio MC, et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. *J Neurol* 2003;**250**:1094–8.
59. Chamelian L, Reis M, Feinstein A. Six-month recovery from mild to moderate traumatic brain injury: the role of *APOE*- $\epsilon 4$  allele. *Brain* 2004;**127**:2621–8.
60. Crawford FC, Vanderploeg RD, Freeman MJ, Singh S, Waisman M, Michaels L, et al. APOE genotype influences acquisition and recall following traumatic brain injury. *Neurology* 2002;**58**:1115–8.
61. Gandy S, Dekosky ST. APOE  $\epsilon 4$  status and traumatic brain injury on the gridiron or the battlefield. *Sci Transl Med* 2012;**4**:134ed4.
62. Benjamin R, Leake A, Ince PG, Perry RH, McKeith IG, Edwardson JA, et al. Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. *Neurodegeneration* 1995;**4**:443–8.
63. Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. *Neurology* 2004;**62**:2005–9.

64. Martinez M, Brice A, Vaughan JR, Zimprich A, Breteler MM, Meo G, et al. Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease. *Am J Med Genet B Neuropsychiatr Genet* 2005;**136B**:72–4.
65. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. *Neurology* 1999;**53**:1308–11.
66. Talha KA, Selina F, Nasir M, Kausar A, Islam T, Perveen RA. Systematic review on apolipoprotein E: a strong genetic cause of hemorrhagic stroke. *Mymensingh Med J* 2020;**29**:1026–32.
67. Alberts MJ, Graffagnino C, McClenny C, DeLong D, Strittmatter W, Saunders AM, et al. ApoE genotype and survival from intracerebral haemorrhage. *Lancet* 1995;**346**:575.
68. Brandon JA, Farmer BC, Williams HC, Johnson LA. APOE and Alzheimer's disease: neuroimaging of metabolic and cerebrovascular dysfunction. *Front Aging Neurosci* 2018;**10**:180.
69. Kish SJ. Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. *Ann N Y Acad Sci* 1997;**826**:218–28.
70. Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nat Rev Neurol* 2019;**15**:501–18.
71. Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer's disease. *J Alzheim Dis* 2018;**62**:1403–16.
72. Morris JK, Honea RA, Vidoni ED, Swerdlow RH, Burns JM. Is Alzheimer's disease a systemic disease?. *Biochim Biophys Acta* 2014;**1842**:1340–9.
73. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. *Mol Brain* 2011;**4**:3.
74. Wilkins HM, Swerdlow RH. Amyloid precursor protein processing and bioenergetics. *Brain Res Bull* 2017;**133**:71–9.
75. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* 1993;**90**:9649–53.
76. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat Genet* 2007;**39**:17–23.
77. Heinonen O, Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Sorvari H, et al. Alzheimer pathology of patients carrying apolipoprotein E  $\epsilon 4$  allele. *Neurobiol Aging* 1995;**16**:505–13.
78. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. *J Clin Invest* 1994;**94**:860–9.
79. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* 1993;**90**:8098–102.
80. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc Natl Acad Sci U S A* 2009;**106**:6820–5.
81. Lim YY, Mormino EC, Alzheimer's Disease Neuroimaging I. APOE genotype and early beta-amyloid accumulation in older adults without dementia. *Neurology* 2017;**89**:1028–34.
82. Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, et al. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE  $\epsilon 4$  genotype. *Brain* 2018;**141**:1828–39.
83. Jansen WJ, Ossenkuppe R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA* 2015;**313**:1924–38.
84. Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F. A multifaceted role for apoE in the clearance of beta-amyloid across the blood–brain barrier. *Neurodegener Dis* 2013;**11**:13–21.
85. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. *J Clin Invest* 2008;**118**:4002–13.
86. Robert J, Button EB, Yuen B, Gilmour M, Kang K, Bahrabadi A, et al. Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. *Elife* 2017;**6**:e29595.
87. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al. ApoE influences amyloid- $\beta$  ( $A\beta$ ) clearance despite minimal apoE/ $A\beta$  association in physiological conditions. *Proc Natl Acad Sci U S A* 2013;**110**:E1807–16.
88. Wisniewski T, Drummond E. APOE–amyloid interaction: therapeutic targets. *Neurobiol Dis* 2020;**138**:104784.
89. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid- $\beta$  peptide clearance. *Sci Transl Med* 2011;**3**:89ra57.
90. Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins. *J Lipid Res* 2017;**58**:824–36.
91. Dafnis I, Stratikos E, Tzinia A, Tsilibary EC, Zannis VI, Chroni A. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42. *J Neurochem* 2010;**115**:873–84.
92. Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types. *Neuron* 2018;**98**:1141–54.e7.
93. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. *Nat Med* 2004;**10**:719–26.
94. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of  $A\beta$  uptake and degradation by astrocytes. *J Biol Chem* 2012;**287**:13959–71.
95. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Abeta. *Neuron* 2008;**58**:681–93.
96. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E- $\epsilon 4$  allele. *Am J Pathol* 2003;**162**:313–9.
97. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. *J Neuropathol Exp Neurol* 2006;**65**:1012–21.
98. Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. *Cold Spring Harb Perspect Med* 2012;**2**:a006379.
99. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JA, Carare RO. Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human APOE  $\epsilon 4$  allele. *PLoS One* 2012;**7**:e41636.
100. Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, et al. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. *Mol Neurodegener* 2016;**11**:74.
101. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with p3 amyloid peptide of Alzheimer's disease to form novel monofibrils. *J Clin Invest* 1994;**94**:860–9.
102. Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, et al. ApoE4 accelerates early seeding of amyloid pathology. *Neuron* 2017;**96**:1024–32.e3.
103. Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, et al. Age-dependent effects of apoE reduction using antisense

- oligonucleotides in a model of beta-amyloidosis. *Neuron* 2017;**96**:1013–23.e4.
104. Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. *Nat Med* 2018;**24**:647–57.
  105. Nuriel T, Peng KY, Ashok A, Dillman AA, Figueroa HY, Apuzzo J, et al. The endosomal–lysosomal pathway is dysregulated by APOE4 expression *in vivo*. *Front Neurosci* 2017;**11**:702.
  106. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. *Curr Alzheimer Res* 2010;**7**:656–64.
  107. Naseri NN, Wang H, Guo J, Sharma M, Luo W. The complexity of tau in Alzheimer's disease. *Neurosci Lett* 2019;**705**:183–94.
  108. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. *Trends Mol Med* 2010;**16**:287–94.
  109. Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of apolipoprotein E  $\epsilon$ 4 with medial temporal tau independent of amyloid- $\beta$ . *JAMA Neurol* 2020;**77**:470–9.
  110. Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without beta-amyloid. *Neurobiol Aging* 2016;**37**:19–25.
  111. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. *Am J Pathol* 2000;**156**:951–64.
  112. Zhao J, Fu Y, Yamazaki Y, Ren Y, Davis MD, Liu CC, et al. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. *Nat Commun* 2020;**11**:5540.
  113. Shi Y, Yamada K, Liddelov SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature* 2017;**549**:523–7.
  114. Zhao N, Liu CC, Van Ingelgom AJ, Linares C, Kurti A, Knight JA, et al. APOE  $\epsilon$ 2 is associated with increased tau pathology in primary tauopathy. *Nat Commun* 2018;**9**:4388.
  115. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekoni L, Wyss-Coray T, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. *Proc Natl Acad Sci U S A* 2003;**100**:10966–71.
  116. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. *Proc Natl Acad Sci U S A* 2001;**98**:8838–43.
  117. Kloske CM, Wilcock DM. The important interface between apolipoprotein E and neuroinflammation in Alzheimer's disease. *Front Immunol* 2020;**11**:754.
  118. Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). *J Biol Chem* 2015;**290**:26043–50.
  119. Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. *J Biol Chem* 2015;**290**:26033–42.
  120. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell* 2015;**160**:1061–71.
  121. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. *Neuron* 2016;**91**:328–40.
  122. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. *N Engl J Med* 2013;**368**:117–27.
  123. Hooli BV, Parrado AR, Mullin K, Yip WK, Liu T, Roehr JT, et al. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. *Neurology* 2014;**83**:1353–8.
  124. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med* 2013;**368**:107–16.
  125. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. *J Neurochem* 2009;**109**:1144–56.
  126. Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. *EMBO Rep* 2017;**18**:1186–98.
  127. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. *J Exp Med* 2005;**201**:647–57.
  128. Ulrich JD, Holtzman DM. TREM2 function in Alzheimer's disease and neurodegeneration. *ACS Chem Neurosci* 2016;**7**:420–7.
  129. Qiao X, Cummins DJ, Paul SM. Neuroinflammation-induced acceleration of amyloid deposition in the APPV<sup>717F</sup> transgenic mouse. *Eur J Neurosci* 2001;**14**:474–82.
  130. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. *J Biol Chem* 2003;**278**:48529–33.
  131. Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, et al. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. *Neurobiol Aging* 2002;**23**:777–85.
  132. Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. *Neurobiol Aging* 2009;**30**:1350–60.
  133. Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, et al. ApoE facilitates the microglial response to amyloid plaque pathology. *J Exp Med* 2018;**215**:1047–58.
  134. Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. *J Exp Med* 2019;**216**:2546–61.
  135. Dafnis I, Tzinia AK, Tsilibary EC, Zannis VI, Chroni A. An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines. *Neuroscience* 2012;**210**:21–32.
  136. Turner RJ, Sharp FR. Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke. *Front Cell Neurosci* 2016;**10**:56.
  137. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an *in vitro* blood–brain barrier model. *J Biol Chem* 2011;**286**:17536–42.
  138. Yamazaki Y, Shinohara M, Yamazaki A, Ren Y, Asmann YW, Kanekiyo T, et al. ApoE (apolipoprotein E) in brain pericytes regulates endothelial function in an isoform-dependent manner by modulating basement membrane components. *Arterioscler Thromb Vasc Biol* 2020;**40**:128–44.
  139. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* 2012;**485**:512–6.
  140. Main BS, Villapol S, Sloley SS, Barton DJ, Parsadanian M, Agbaegbu C, et al. Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury. *Mol Neurodegener* 2018;**13**:17.
  141. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. *J Alzheim Dis* 2010;**20**:843–54.
  142. Morris JK, Vidoni ED, Honea RA, Burns JM. Impaired glycemia and Alzheimer's disease. *Neurobiol Aging* 2014;**35**:e23.
  143. Silva DF, Selfridge JE, Lu J, L E, Roy N, Hutfles L, et al. Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI hybrid cell lines. *Hum Mol Genet* 2013;**22**:3931–46.

144. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, et al. Brain cytochrome oxidase in Alzheimer's disease. *J Neurochem* 1992;**59**:776–9.
145. Parker WD Jr. Cytochrome oxidase deficiency in Alzheimer's disease. *Ann N Y Acad Sci* 1991;**640**:59–64.
146. Parker WD Jr, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. *Neurology* 1990;**40**:1302–3.
147. Chakravorty A, Jetto CT, Manjithaya R. Dysfunctional mitochondria and mitophagy as drivers of Alzheimer's disease pathogenesis. *Front Aging Neurosci* 2019;**11**:311.
148. Jagust WJ, Landau SM. Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. *J Neurosci* 2012;**32**:18227–33.
149. Johnson LA, Torres ER, Impey S, Stevens JF, Raber J. Apolipoprotein E4 and insulin resistance interact to impair cognition and alter the epigenome and metabolome. *Sci Rep* 2017;**7**:43701.
150. Arbones-Mainar JM, Johnson LA, Torres-Perez E, Garcia AE, Perez-Diaz S, Raber J, et al. Metabolic shifts toward fatty-acid usage and increased thermogenesis are associated with impaired adipogenesis in mice expressing human APOE4. *Int J Obes (Lond)* 2016;**40**:1574–81.
151. Liu CC, Hu J, Tsai CW, Yue M, Melrose HL, Kanekiyo T, et al. Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. *J Neurosci* 2015;**35**:5851–9.
152. Zhao N, Liu CC, Van Ingelgom AJ, Martens YA, Linares C, Knight JA, et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. *Neuron* 2017;**96**:115–29. e5.
153. Nakamura T, Watanabe A, Fujino T, Hosono T, Michikawa M. Apolipoprotein E4 (1–272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. *Mol Neurodegener* 2009;**4**:35.
154. Tambini MD, Pera M, Kanter E, Yang H, Guardia-Laguarta C, Holtzman D, et al. ApoE4 upregulates the activity of mitochondria-associated ER membranes. *EMBO Rep* 2016;**17**:27–36.
155. Liang T, Hang W, Chen J, Wu Y, Wen B, Xu K, et al. ApoE4 (delta272–299) induces mitochondrial-associated membrane formation and mitochondrial impairment by enhancing GRP75-modulated mitochondrial calcium overload in neuron. *Cell Biosci* 2021;**11**:50.
156. Yin J, Nielsen M, Carcione T, Li S, Shi J. Apolipoprotein E regulates mitochondrial function through the PGC-1 $\alpha$ –sirtuin 3 pathway. *Aging (Albany NY)* 2019;**11**:11148–56.
157. James R, Searcy JL, Le Bihan T, Martin SF, Gliddon CM, Povey J, et al. Proteomic analysis of mitochondria in APOE transgenic mice and in response to an ischemic challenge. *J Cerebr Blood Flow Metabol* 2012;**32**:164–76.
158. Schmukler E, Solomon S, Simonovitch S, Goldshmit Y, Wolfson E, Michaelson DM, et al. Altered mitochondrial dynamics and function in APOE4-expressing astrocytes. *Cell Death Dis* 2020;**11**:578.
159. Yin J, Reiman EM, Beach TG, Serrano GE, Sabbagh MN, Nielsen M, et al. Effect of ApoE isoforms on mitochondria in Alzheimer disease. *Neurology* 2020;**94**:e2404–11.
160. Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE  $\epsilon$ 4 allele, the major late-onset Alzheimer's susceptibility gene. *J Alzheim Dis* 2010;**22**:307–13.
161. Perkins M, Wolf AB, Chavira B, Shonebarger D, Meckel JP, Leung L, et al. Altered energy metabolism pathways in the posterior cingulate in young adult apolipoprotein E  $\epsilon$ 4 carriers. *J Alzheim Dis* 2016;**53**:95–106.
162. Mulica P, Grunewald A, Pereira SL. Astrocyte–neuron metabolic crosstalk in neurodegeneration: a mitochondrial perspective. *Front Endocrinol (Lausanne)* 2021;**12**:668517.
163. Williams HC, Farmer BC, Piron MA, Walsh AE, Bruntz RC, Gentry MS, et al. APOE alters glucose flux through central carbon pathways in astrocytes. *Neurobiol Dis* 2020;**136**:104742.
164. Wilkins HM, Wang X, Menta BW, Koppel SJ, Bothwell R, Becker AM, et al. Bioenergetic and inflammatory systemic phenotypes in Alzheimer's disease APOE  $\epsilon$ 4-carriers. *Aging Cell* 2021;**20**:e13356.
165. Wilkins HM, Koppel SJ, Bothwell R, Mahnken J, Burns JM, Swerdlow RH. Platelet cytochrome oxidase and citrate synthase activities in APOE  $\epsilon$ 4 carrier and non-carrier Alzheimer's disease patients. *Redox Biol* 2017;**12**:828–32.
166. Ignatius MJ, Gebicke-Harter PJ, Skene JH, Schilling JW, Weisgraber KH, Mahley RW, et al. Expression of apolipoprotein E during nerve degeneration and regeneration. *Proc Natl Acad Sci U S A* 1986;**83**:1125–9.
167. Li FQ, Fowler KA, Neil JE, Colton CA, Vitek MP. An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. *J Pharmacol Exp Therapeut* 2010;**334**:106–15.
168. Raman S, Brookhouser N, Brafman DA. Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk. *Neurobiol Dis* 2020;**138**:104788.
169. Yin C, Guo ZD, He ZZ, Wang ZY, Sun XC. Apolipoprotein E affects *in vitro* axonal growth and regeneration via the MAPK signaling pathway. *Cell Transplant* 2019;**28**:691–703.
170. Mahley RW, Huang Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. *Neuron* 2012;**76**:871–85.
171. Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. *Exp Neurol* 1994;**125**:163–71.
172. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. *Cell* 2012;**148**:1204–22.
173. Bellosta S, Nathan BP, Orth M, Dong LM, Mahley RW, Pitas RE. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. *J Biol Chem* 1995;**270**:27063–71.
174. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth *in vitro*. *Science* 1994;**264**:850–2.
175. Nathan BP, Chang KC, Bellosta S, Brisch E, Ge N, Mahley RW, et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. *J Biol Chem* 1995;**270**:19791–9.
176. Johnson LA, Olsen RH, Merckens LS, DeBarber A, Steiner RD, Sullivan PM, et al. Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner. *Neurobiol Dis* 2014;**64**:150–62.
177. Fagan AM, Bu G, Sun Y, Daugherty A, Holtzman DM. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. *J Biol Chem* 1996;**271**:30121–5.
178. Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, Bu G, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. *Proc Natl Acad Sci U S A* 1995;**92**:9480–4.
179. Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. *Proc Natl Acad Sci U S A* 2010;**107**:12011–6.
180. Korwek KM, Trotter JH, Ladu MJ, Sullivan PM, Weeber EJ. ApoE isoform-dependent changes in hippocampal synaptic function. *Mol Neurodegener* 2009;**4**:21.
181. Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Ye GL, et al. ApoE isoform affects LTP in human targeted replacement mice. *Neuroreport* 2004;**15**:2655–8.
182. Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD, et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. *Alzheimer Dis Assoc Disord* 1999;**13**:216–21.

183. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet* 1993;**342**:697–9.
184. Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer's Disease Neuroimaging Initiative Investigators. Sex modifies the APOE-related risk of developing Alzheimer disease. *Ann Neurol* 2014;**75**:563–73.
185. Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. *Ann N Y Acad Sci* 2004;**1019**:24–8.
186. Payami H, Montee KR, Kaye JA, Bird TD, Yu CE, Wijsman EM, et al. Alzheimer's disease, apolipoprotein E4, and gender. *JAMA* 1994;**271**:1316–7.
187. Gamache J, Yun Y, Chiba-Falek O. Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders. *Dis Model Mech* 2020;**13**:dmm045211.
188. He LN, Recker RR, Deng HW, Dvornyk V. A polymorphism of apolipoprotein E (APOE) gene is associated with age at natural menopause in Caucasian females. *Maturitas* 2009;**62**:37–41.
189. Meng FT, Wang YL, Liu J, Zhao J, Liu RY, Zhou JN. ApoE genotypes are associated with age at natural menopause in Chinese females. *Age (Dordr)* 2012;**34**:1023–32.
190. Gallart-Palau X, Lee BS, Adav SS, Qian J, Serra A, Park JE, et al. Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer's disease with cerebrovascular disease. *Mol Brain* 2016;**9**:27.
191. Operto G, Cacciaglia R, Grau-Rivera O, Falcon C, Brugulat-Serrat A, Rodenas P, et al. White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes. *Alzheimer's Res Ther* 2018;**10**:48.
192. Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Osorio RS, et al. Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. *PLoS One* 2017;**12**:e0185926.
193. Ding F, Yao J, Rettberg JR, Chen S, Brinton RD. Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. *PLoS One* 2013;**8**:e79977.
194. Ding F, Yao J, Zhao L, Mao Z, Chen S, Brinton RD. Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. *PLoS One* 2013;**8**:e59825.
195. Cheng X, McAsey ME, Li M, Randall S, Cady C, Nathan BP, et al. Estradiol replacement increases the low-density lipoprotein receptor related protein (LRP) in the mouse brain. *Neurosci Lett* 2007;**417**:50–4.
196. De Marinis E, Martini C, Trentalance A, Pallottini V. Sex differences in hepatic regulation of cholesterol homeostasis. *J Endocrinol* 2008;**198**:635–43.
197. Zhao L, Morgan TE, Mao Z, Lin S, Cadenas E, Finch CE, et al. Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles. *PLoS One* 2012;**7**:e31267.
198. Ratnakumar A, Zimmerman SE, Jordan BA, Mar JC. Estrogen activates Alzheimer's disease genes. *Alzheimers Dement (N Y)* 2019;**5**:906–17.
199. Guimaraes RA, Asth L, Engelberth RC, Cavalcante Jde S, Soares-Rachetti Vde P, Gavioli EC. Spontaneous failure of the estrous cycle induces anxiogenic-related behaviors in middle-aged female mice. *Physiol Behav* 2015;**147**:319–23.
200. Yong SM, Lim ML, Low CM, Wong BS. Reduced neuronal signaling in the ageing apolipoprotein-E4 targeted replacement female mice. *Sci Rep* 2014;**4**:6580.
201. Farmer BC, Williams HC, Devanney NA, Piron MA, Nation GK, Carter DJ, et al. APOE4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis. *Mol Neurodegener* 2021;**16**:62.
202. Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting apolipoprotein E function in Alzheimer's disease. *Mol Neurodegener* 2020;**15**:8.
203. Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer's disease. *BMC Med* 2019;**17**:64.
204. Hinrich AJ, Jodelka FM, Chang JL, Brutman D, Bruno AM, Briggs CA, et al. Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides. *EMBO Mol Med* 2016;**8**:328–45.
205. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. *J Biol Chem* 2010;**285**:34144–54.
206. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. *Science* 2012;**335**:1503–6.
207. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. *Alzheimer's Res Ther* 2016;**8**:4.
208. Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, et al. A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects. *Alzheimers Dement (N Y)* 2016;**2**:110–20.
209. Boehm-Cagan A, Bar R, Liraz O, Bielicki JK, Johansson JO, Michaelson DM. ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies. *J Alzheim Dis* 2016;**54**:1219–33.
210. Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, et al. MicroRNA-33 regulates ApoE lipidation and amyloid-beta metabolism in the brain. *J Neurosci* 2015;**35**:14717–26.
211. Jan A, Karasinska JM, Kang MH, de Haan W, Ruddle P, Kaur A, et al. Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. *Neurosci Lett* 2015;**598**:66–72.
212. Chernick D, Ortiz-Valle S, Jeong A, Swaminathan SK, Kandimalla KK, Rebeck GW, et al. High-density lipoprotein mimetic peptide 4F mitigates amyloid-beta-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia. *J Neurochem* 2018;**147**:647–62.
213. Wang H, Durham L, Dawson H, Song P, Warner DS, Sullivan PM, et al. An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. *Neuroscience* 2007;**144**:1324–33.
214. Sarantseva S, Timoshenko S, Bolshakova O, Karaseva E, Rodin D, Schwarzman AL, et al. Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic *Drosophila* model of Alzheimer's disease. *PLoS One* 2009;**4**:e8191.
215. Krishnamurthy K, Cantillana V, Wang H, Sullivan PM, Kolls BJ, Ge X, et al. ApoE mimetic improves pathology and memory in a model of Alzheimer's disease. *Brain Res* 2020;**1733**:146685.
216. James ML, Troy J, Nowacki N, Komisarow J, Swisher CB, Tucker K, et al. CN-105 in participants with acute supratentorial intracerebral hemorrhage (CATCH) trial. *Neurocritical Care* 2021. Available from: <https://link.springer.com/article/10.1007%2Fs12028-021-01287-0>.
217. Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. *J Biol Chem* 2012;**287**:5253–66.
218. Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. *J Exp Med* 2012;**209**:2149–56.
219. Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, et al. Anti-ApoE antibody given after plaque onset decreases Aβ

- accumulation and improves brain function in a mouse model of A $\beta$  amyloidosis. *J Neurosci* 2014;**34**:7281–92.
220. Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. *J Clin Invest* 2018;**128**:2144–55.
221. Wadhvani AR, Affaneh A, Van Gulden S, Kessler JA. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease. *Ann Neurol* 2019;**85**:726–39.
222. Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, et al. Gene transfer of human *APOE* isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. *Sci Transl Med* 2013;**5**:212ra161.
223. Cabral DF, Rice J, Morris TP, Rundek T, Pascual-Leone A, Gomes-Osman J. Exercise for brain health: an investigation into the underlying mechanisms guided by dose. *Neurotherapeutics* 2019;**16**:580–99.
224. Koppel SJ, Swerdlow RH. Neuroketotherapeutics: a modern review of a century-old therapy. *Neurochem Int* 2018;**117**:114–25.
225. Ridler C. Exercise wards off Alzheimer disease by boosting neurogenesis and neuroprotective factors. *Nat Rev Neurol* 2018;**14**:632.
226. Strohle A, Schmidt DK, Schultz F, Fricke N, Staden T, Hellweg R, et al. Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. *Am J Geriatr Psychiatry* 2015;**23**:1234–49.
227. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and Alzheimer disease mortality. *Neurology* 2007;**69**:1084–93.
228. Sullivan PM. Influence of Western diet and APOE genotype on Alzheimer's disease risk. *Neurobiol Dis* 2020;**138**:104790.
229. Beal E. Alzheimer disease: eating a combination of healthy foods lowers the risk of developing Alzheimer disease. *Nat Rev Neurol* 2010;**6**:295.